NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

flipper44
RE: abeta Post # 660684
01/02/2024 03:33 AM
Post
# of 660949
In that Meso trial, Merck’s collaborators used subcutaneous injection, which is inferior to intradermal. (Note: DCVax-l is injected intradermally) (Extra note: It looks like Merck is working its way up to a DC dose that will cause crowding)

Note: MESOVAX was the name of the trial, not the product.

Methods
MESOVAX is a Ph1b study evaluating safety of P 200 mg Q3W and an autologous DCvax administered subcutaneously Q3W for a maximum of 6 cycles, in pretreated metastatic M patients (pts). Primary endpoint was safety; secondary were PD-L1 expression variations defined by immunohistochemistry (IHC) and efficacy (objective response rate [ORR], duration of response [DOR], progression-free survival [PFS], overall survival [OS]).

. https://cslide.ctimeetingtech.com/immuno23hybrid/attendee/confcal/show/session/34%0A